Athena Pharmaceutiques Oral Dispersible Tablets

Athena Pharmaceutiques Oral Dispersible Tablets

X

[{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celsius Therapeutics Signs Research Agreements with Leading Academic Centers to Develop Insights into Inflammatory Bowel Disease Biology","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$700.0 million","upfrontCash":"Undisclosed","newsHeadline":"Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Applied BioMath","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Applied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery"},{"orgOrder":0,"company":"Celsius Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody at 18th Congress of ECCO - Inflammatory Bowel Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Celsius Therapeutics

Celsius Therapeutics

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

8 News

8 News

DEVELOPMENTS

4 Drug(s) in Development

4 Drug(s) in Development

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Celsius Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody at 18th Congress of ECCO - Inflammatory Bowel Diseases

Details:

CEL383, an anti-TREM1 antibody, a myeloid target with a central role in inflammatory bowel disease. TREM1 is the first of these targets, an amplifier of mucosal inflammation that resides at the intersection of the microbiome and the immune system.

Lead Product(s): CEL383

Therapeutic Area: Gastroenterology Product Name: CEL383

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2023

ASK
US

Upload
your Pipeline Activity

Celsius Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Applied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease

Details:

Under the agreement, Celsius Therapeutics will collaborate for the development of a systems pharmacology model of a monoclonal antibody for the treatment of inflammatory bowel disease (IBD).

Lead Product(s): Undisclosed

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Applied BioMath

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration October 04, 2022

ASK
US

Upload
your Pipeline Activity

Celsius Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer

Details:

Under the terms of collaboration, Celsius will analyze hundreds of samples from defined CRC patient populations using its proprietary single-cell genomics platform and will work to identify and validate new drug targets during the three-year research period.

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Servier

Deal Size: $700.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration December 21, 2020

ASK
US

Upload
your Pipeline Activity

Celsius Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Celsius Therapeutics Signs Research Agreements with Leading Academic Centers to Develop Insights into Inflammatory Bowel Disease Biology

Details:

Celsius will partner with leading academic scientists to access patient tissue samples and apply its proprietary single-cell genomics platform and machine learning capabilities to discover new insights into inflammatory bowel disease (IBD).

Lead Product(s): Undisclosed

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: University of Oxford

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 01, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY